LKFT·Nasdaq·US
Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biopharmaceutical company focused on developing medicines for severe diseases in oncology and immunology. Its pipeline includes clinical-stage programs such as CAR-T candidates and autoimmune disease assets, often advanced through partnerships.
Recent Activity
Updated Oct 17, 2026
–Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of the cancer cell therapies previously owned by Lakefront Biotherapeutics, the company formerly known as Galapagos.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.